Ascendis Pharma A/S
ASND
NASDAQ·Healthcare·Biotechnology·Mkt cap $16.8B
$270.56
▼ -0.21%
P/E
21.85
Mkt Cap
$16.8B
52-Wk Range
$186.05–$282.15
52-Week Range
$186.05 - $282.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 31.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary TransCon technology platform enabling sustained-release drug delivery
- FDA-approved SKYTROFA with significant market opportunity in GHD treatment
- Strong intellectual property portfolio with multiple patent protections
- Experienced management team with proven track record in biopharmaceutical development
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Moderate growth ahead
SKYTROFA market penetration and label expansion in pediatric and adult populations
Value
Trading at 0.8x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+31.5% over 3m
Quality
Excellent
High-growth business (107% revenue growth, 90% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ASND right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of $3.29 vs $1.71 consensus (+92.4% surprise). Revenue of $387.5M vs $376.8M expected (+2.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+92.4%
Revenue trend · last 8Q
—
—
+5%
+339%
+269%
+41%
+112%
+118%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$67.8M
$203.9M
$118.4M
$185.3M
$250.5M
$287.4M
$250.7M
$402.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
61.0%
Wall Street consensus
11 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Sep 1, 2026
vs Industry
How ASND stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related